Glenmark posts Rs 102.6 cr net profit

Image
BS Reporter Mumbai
Last Updated : Jan 20 2013 | 12:52 AM IST

Better perormance by various business verticals helped Glenmark Pharmaceuticals (GPL) post a net profit of Rs 102.6 crore for the fourth quarter ended March as compared to a loss of Rs 120.6 crore for the previous corresponding quarter.

Glenmark’s consolidated revenue for the quarter was Rs 709.1 crore, as against Rs 491 crore, an increase of 44.4 per cent.

"All businesses and regions have performed well and we continue to remain optimistic about growth for the current financial year,” Glenn Saldanha, chief executive and managing director commented on the performance.

Sales for the formulation business in India increased to Rs 218.4 crore for the quarter from Rs161.6 crore in the previous corresponding quarter, recording a growth of over 35 per cent. Revenue from Africa, Asia and CIS region was at Rs 136.9 crore, three times more than the previous corresponding quarter. Glenmark’s revenue from its Latin American and Caribbean operations was at Rs 34.5 crore, as against Rs 26.8 crore, a growth of 28.7 per cent.

Glenmark Europe’s operations recorded revenue of Rs 45.9 crore as compared to Rs 38.3 crore for the previous corresponding quarter. Its generics business in the US recorded revenues of Rs 185.2 crore for the fourth quarter, as against revenue of Rs 1,56.3 crore, an increase of about 18 per cent. Revenue from sale of active pharmaceutical ingredients to regulated and semi-regulated markets globally was Rs 70.2 crore as against Rs 50.5 crore for fourth quarter of the previous year, recording an increase of 39 per cent.

For the financial year 2009-10, Glenmark’s consolidated revenue increased to Rs 2484.8 crore as against Rs 2,093 crore, a growth of 18.7 percent.

The consolidated net profit for the financial year was at Rs 331 crore as compared to Rs 193.4 crore for the previous financial year, an increase of 71.14 per cent.

Revenue from the generics business was at Rs 1,050 crore, as against Rs 985.7 crore registering growth of 7 per cent. The Speciality formulation business registered revenue of Rs 1,434.8 crore as against Rs 1,107.2 crore, registering growth of 30 per cent.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 28 2010 | 5:58 PM IST

Next Story